Skip to main content

Table 2 Patient demographic and histological data

From: Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation

Variables

N (%)

Gender

 

 Male

295 (44.4)

 Female

369 (55.6)

Age

 

 <70

372 (56.0)

 ≥70

292 (44.0)

Preoperative renal function

 

 eGFR ≥ 60

298 (44.9)

 60 >eGFR ≥15

316 (47.6)

 eGFR <15

50 (7.5)

Side

 

 Left

326 (49.1)

 Right

338 (50.9)

Transplant recipient

 

 No

653 (98.3)

 Yes

11 (1.7)

Ipsilateral hydronephrosis

 

 Absence

290 (43.7)

 Presence

374 (56.3)

Tobacco consumption

 

 No

543 (81.8)

 Yes

121 (18.2)

Surgical approach

 

 Open

445 (67.0)

 Laparoscopic

219 (33.0)

Tumor size

 

 ≤3 cm

373 (56.2)

 >3 cm

291 (43.8)

Architecture

 

 Papillary

515 (77.6)

 Sessile

149 (22.4)

Ureteroscopy

 

 No

583 (87.8)

 Yes

81 (12.2)

Location

 

 Pelvis

368 (55.4)

 Ureter

296 (44.6)

 Upper ureter

58 (8.7)

 Middle ureter

68 (10.2)

 Lower ureter

170 (25.6)

Multifocality

 

 No

505 (76.1)

 Yes

159 (23.9)

CIS

 

 Absence

645 (97.1)

 Presence

19 (2.9)

Contralateral recurrence

 

 No

634 (95.5)

 Yes

30 (4.5)

Bladder recurrence

 

 No

441 (66.4)

 Yes

223 (33.6)

 Before contralateral UTUC

209 (31.5)

 Concomitant and after contralateral UTUC

14 (2.1)

Tumor stage

 

 Ta or T1

221 (33.3)

 T2

237 (35.7)

 T3

194 (29.2)

 T4

12 (1.8)

Tumor grade

 

 G1

21 (3.2)

 G2

360 (54.2)

 G3

283 (42.6)

N status

 

 N+

47 (7.1)

 cN0 or pN0

617 (92.9)

Adjuvant therapy

 

 No

641 (96.5)

 Yes

23 (3.5)

  1. eGFR = estimated glomerular filtration rate; CIS = carcinoma in situ; UTUC = upper tract urothelial carcinoma.